CBIO - タ―ガセプト （Catalyst Biosciences Inc. ）

AYTU has seen its SMA50 which is now -23.34%. In looking the SMA 200 we see that the stock has seen a -56.74%. CBIO has seen its SMA50 which is … The post Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) appeared first on Stocks Equity .

Catalyst Biosciences Inc. (CBIO)’s stock has witnessed a price hike of 27.46% from the previous close with its current price standing at $0.31. Its current price is -23.98% under its 52-week high of $0.40 and 436.90% more than its 52-week low of $0.06. Based on the past 30-day period, the stock price is -15.42% below […]

Entered into an acquisition deal of 3 programs YONGIN, South Korea , Feb. 28, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea , announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : CBIO) to acquire 3 programs related to the orphan hematology disorders. This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development. In its previous clinical development trials, "MarzAA" demonstrated efficacy and safety as a treatment for rare bleeding disorders. More significantly, "MarzAA", unlike majority of existing therapeutics, is delivered by subcutaneous injection, making it more convenient to administer and less burdensome for the patients, who require life-long treatment. It is GC Biopharma''s plan to continue development of the asset in pursuit of launching a first-in-class novel drug that will pave the way for the company to make inroads into the global markets, including the US and other advanced markets.

In last trading session, Catalyst Biosciences Inc. (NASDAQ:CBIO) saw 0.57 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $0.29 trading at -$0.01 or -2.99% at ring of the bell on the day assigns it a market valuation of $10.39M. That closing price of CBIO’s stock is … With 79.31% From The Low, Is Catalyst Biosciences Inc. (NASDAQ:CBIO) Up For More Gains? Read More »

AYTU has seen its SMA50 which is now -23.34%. In looking the SMA 200 we see that the stock has seen a -56.74%. CBIO has seen its SMA50 which is … The post Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) appeared first on Stocks Equity .

Catalyst Biosciences Inc. (CBIO)’s stock has witnessed a price hike of 27.46% from the previous close with its current price standing at $0.31. Its current price is -23.98% under its 52-week high of $0.40 and 436.90% more than its 52-week low of $0.06. Based on the past 30-day period, the stock price is -15.42% below […]

Entered into an acquisition deal of 3 programs YONGIN, South Korea , Feb. 28, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea , announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : CBIO) to acquire 3 programs related to the orphan hematology disorders. This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development. In its previous clinical development trials, "MarzAA" demonstrated efficacy and safety as a treatment for rare bleeding disorders. More significantly, "MarzAA", unlike majority of existing therapeutics, is delivered by subcutaneous injection, making it more convenient to administer and less burdensome for the patients, who require life-long treatment. It is GC Biopharma''s plan to continue development of the asset in pursuit of launching a first-in-class novel drug that will pave the way for the company to make inroads into the global markets, including the US and other advanced markets.

In last trading session, Catalyst Biosciences Inc. (NASDAQ:CBIO) saw 0.57 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $0.29 trading at -$0.01 or -2.99% at ring of the bell on the day assigns it a market valuation of $10.39M. That closing price of CBIO’s stock is … With 79.31% From The Low, Is Catalyst Biosciences Inc. (NASDAQ:CBIO) Up For More Gains? Read More »

AYTU has seen its SMA50 which is now -23.34%. In looking the SMA 200 we see that the stock has seen a -56.74%. CBIO has seen its SMA50 which is … The post Griping stocks: Aytu BioPharma, Inc. (NASDAQ:AYTU 1.76%), Catalyst Biosciences, Inc. (NASDAQ:CBIO -2.83%) appeared first on Stocks Equity .

Catalyst Biosciences Inc. (CBIO)’s stock has witnessed a price hike of 27.46% from the previous close with its current price standing at $0.31. Its current price is -23.98% under its 52-week high of $0.40 and 436.90% more than its 52-week low of $0.06. Based on the past 30-day period, the stock price is -15.42% below […]

Entered into an acquisition deal of 3 programs YONGIN, South Korea , Feb. 28, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea , announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : CBIO) to acquire 3 programs related to the orphan hematology disorders. This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development. In its previous clinical development trials, "MarzAA" demonstrated efficacy and safety as a treatment for rare bleeding disorders. More significantly, "MarzAA", unlike majority of existing therapeutics, is delivered by subcutaneous injection, making it more convenient to administer and less burdensome for the patients, who require life-long treatment. It is GC Biopharma''s plan to continue development of the asset in pursuit of launching a first-in-class novel drug that will pave the way for the company to make inroads into the global markets, including the US and other advanced markets.

In last trading session, Catalyst Biosciences Inc. (NASDAQ:CBIO) saw 0.57 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $0.29 trading at -$0.01 or -2.99% at ring of the bell on the day assigns it a market valuation of $10.39M. That closing price of CBIO’s stock is … With 79.31% From The Low, Is Catalyst Biosciences Inc. (NASDAQ:CBIO) Up For More Gains? Read More »

INBS has seen its SMA50 which is now 210.42%. In looking the SMA 200 we see that the stock has seen a 95.88%. CBIO has seen its SMA50 which is … The post This stocks will Fire Up Your investment: Intelligent Bio Solutions Inc. (NASDAQ:INBS -9.24%), Catalyst Biosciences, Inc. (NASDAQ:CBIO 7.07%) appeared first on Stocks Equity .